The two lines I like the most from the report:
Collaboration with global leader in the clinical research of neurological aspects of Long COVID-19 Dr Koralnik to continue with application for grant funding
- they are going to do the hard work of grant funding applications not ANP.
Company plans to review its new patent applications with targeted pharmaceutical and diagnostic companies for potential commercial discussions
- Commercialisation discussions = if successful that equates to dollars in the bank and therefore any CR is smaller or not needed at??
The two lines I like the most from the report:Collaboration with...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
